This Patient Responsibility and Compliance Agreement ("Agreement") is entered into between Leanova Health ("Leanova"), its affiliated medical practitioners, clinical staff, employees, contractors, and partner service providers (collectively, the "Leanova Team"), and the undersigned individual ("Patient"). This Agreement constitutes the Patient's informed consent to medical assessment and treatment, acknowledgment of responsibilities and obligations, and waiver of certain claims, all as set out below.

Part A  —  Patient Identification and Eligibility

Clause 1.  Accuracy of Patient Information

The Patient affirms that all personal information supplied to Leanova — including full name, date of birth, address, contact details, current medications, medical history, and any other information provided during registration or assessment — is accurate, current, and complete to the best of the Patient's knowledge. The Patient acknowledges that any omission or misrepresentation of information may materially affect the safety, appropriateness, and legal validity of treatment provided under this Agreement.

Clause 2.  Age and Legal Capacity

The Patient confirms that they are at least 18 years of age and are a person of sound mind and judgment. The Patient has the legal capacity to enter into a binding agreement and to consent to medical treatment under the applicable laws of India. Where services are sought on behalf of a minor, the parent or legal guardian must sign this Agreement on the minor's behalf and accepts full responsibility for all obligations contained herein.

Clause 3.  Jurisdictional Eligibility

The Patient confirms that they are legally permitted under the laws of their country and state of residence to receive the requested treatment, consultations, and medications, and that they enter into this Agreement in compliance with all applicable laws. The Patient accepts sole responsibility for determining and maintaining such eligibility.

Part B  —  Nature and Purpose of the Leanova Program

Clause 4.  Program Overview

The Patient acknowledges that Leanova provides a medically supervised program focused on the long-term evaluation, management, and treatment of obesity and related metabolic, hormonal, and psychological conditions. The Patient understands that obesity is recognised under current medical evidence as a chronic, relapsing, multifactorial disease requiring sustained medical and behavioural intervention — not a failure of willpower or character.

Leanova's treatment framework may include, but is not limited to:

• Clinical assessment and metabolic profiling;

• Lifestyle modification and structured nutritional guidance;

• Behavioural counselling and psychological support;

• Pharmacotherapy including GLP-1 receptor agonists, dual incretin agonists, and other approved anti-obesity medications;

• Telemedicine consultations and digital follow-up;

• Referral to specialist physicians, surgeons, or allied health professionals as clinically indicated.

Clause 5.  Telemedicine Model

The Patient understands that Leanova operates primarily through telemedicine — delivering medical consultations, clinical assessments, and follow-up care via digital channels including video, audio, WhatsApp, and online platforms. The Patient accepts that telemedicine has inherent limitations compared to in-person consultation, including reduced ability to perform physical examination, and accepts these limitations voluntarily as a condition of enrolling in the program.

Part C  —  Consent to Assessment and Medical Evaluation

Clause 6.  Consent to Clinical Assessment

The Patient grants Leanova and its affiliated physicians full permission to conduct all examinations, assessments, and investigations deemed clinically necessary. These may include, without limitation:

• Measurement of height, weight, body mass index (BMI), waist circumference, and vital signs;

• Review and interpretation of laboratory investigations, including but not limited to lipid profile, HbA1c, fasting glucose, liver function tests (LFTs), kidney function tests (eGFR, creatinine), thyroid hormones (TSH, T3, T4), vitamin levels (D, B12), and complete blood count;

• Hormonal assessment including insulin, testosterone, anti-Müllerian hormone (AMH), and other markers relevant to metabolic or reproductive health;

• Mental health screening using validated clinical tools where clinically appropriate;

• Screening for obstructive sleep apnoea, non-alcoholic fatty liver disease (NAFLD), insulin resistance, and other obesity-related comorbidities;

• Review of uploaded documents including previous prescriptions, diagnostic reports, and clinical photographs.

The Patient acknowledges that such evaluations are integral to determining safe and clinically appropriate treatment and consents to their performance.

Part D  —  Authorisation for Treatment and Medical Management

Clause 7.  Authorisation for Treatment

The Patient authorises the Leanova physician to recommend and, where appropriate, prescribe or administer treatment modalities as clinically indicated. These may include:

• Personalised nutritional plans adapted to Indian dietary culture and patient preferences;

• Structured physical activity and resistance training guidance;

• Behavioural health coaching, habit modification techniques, and psychological support referrals;

• Pharmacotherapy, including semaglutide (GLP-1 receptor agonist), tirzepatide (dual GIP/GLP-1 receptor agonist), orlistat, or any other medication approved under Indian regulatory guidelines for obesity or metabolic management;

• Supplementation where clinically indicated (e.g., Vitamin D, B12, iron, protein support);

• Referral to external specialists including endocrinologists, cardiologists, gynaecologists, gastroenterologists, psychologists, or bariatric surgeons, as appropriate.

Clause 8.  Understanding of Treatment Variability

The Patient understands and accepts that:

• No specific weight loss target, rate of progress, or health outcome is guaranteed or promised by Leanova or its physicians;

• Pharmacotherapy efficacy varies significantly between individuals due to genetic, hormonal, metabolic, and behavioural factors;

• The prescribed treatment plan may require adjustment over time, including dose changes, medication switches, or program modifications, based on clinical response and safety monitoring;

• Long-term program engagement is generally necessary for sustained outcomes, and early discontinuation significantly increases the risk of weight regain.

Part E  —  Disclosure of Risks and Limitations

Clause 9.  Risks Associated with Treatment

The Patient acknowledges that Leanova has informed them of the known and reasonably foreseeable risks associated with each component of the treatment program. The Patient confirms they have had adequate opportunity to ask questions and receive satisfactory answers before signing this Agreement.

9.1  Lifestyle and Behavioural Interventions

These may be associated with temporary fatigue, hunger, emotional discomfort, musculoskeletal soreness, dizziness, or difficulty adjusting to behavioural change. Individual responses to dietary restriction and exercise vary and will be managed clinically.

9.2  Pharmacotherapy

GLP-1 receptor agonists and dual incretin agonists (e.g., semaglutide, tirzepatide) may cause adverse effects including, but not limited to, the following:

• Gastrointestinal effects: nausea, vomiting, diarrhoea, constipation, abdominal discomfort, acid reflux, reduced appetite, and dyspepsia — most common during dose escalation and typically transient;

• Dehydration and electrolyte disturbance, particularly if gastrointestinal symptoms are severe;

• Injection-site reactions: redness, swelling, bruising, or nodule formation;

• Headache, fatigue, and dizziness;

• Gallbladder disease, including cholelithiasis (gallstones) and cholecystitis;

• Hypoglycaemia when used in combination with insulin secretagogues or insulin — the Patient must inform all treating physicians of all medications being taken;

• Rare but serious events including acute pancreatitis, acute kidney injury (typically secondary to dehydration), and tachycardia;

• Theoretical risk of thyroid C-cell tumours noted in rodent studies; clinical significance in humans remains under investigation. Patients with personal or family history of medullary thyroid carcinoma or MEN-2 syndrome must disclose this before commencing treatment;

• Potential worsening of pre-existing diabetic retinopathy in some patients with type 2 diabetes.

9.3  Laboratory Investigations

Venepuncture for blood tests may cause temporary bruising, minor bleeding, localised discomfort, or, rarely, fainting. These are standard risks of routine clinical investigations.

9.4  Psychological and Behavioural Risks

Clinical assessments may identify pre-existing mental health conditions including anxiety, depression, disordered eating, or body image concerns requiring specialist intervention. The Patient consents to such screening and, where relevant, to referral for appropriate support.

Clause 10.  Contraindications and Safety Exclusions

The Patient declares that they have truthfully disclosed all relevant medical conditions and confirms, to the best of their knowledge, that none of the following absolute contraindications apply, unless explicitly disclosed and reviewed by the Leanova physician:

• Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN-2);

• Active or recent (within 12 months) pancreatitis;

• Pregnancy, breastfeeding, or active attempt to conceive;

• Type 1 diabetes mellitus;

• Severe renal impairment (eGFR < 15 mL/min/1.73m²) or end-stage renal disease;

• Severe active eating disorder (anorexia nervosa, severe bulimia nervosa) unless under concurrent specialist psychiatric care;

• Known hypersensitivity to any ingredient of the prescribed medication;

• Active severe psychiatric illness not under stable specialist management.

Where any of the above conditions are present or uncertain, the Patient agrees to disclose this to the Leanova physician prior to commencement of any pharmacotherapy.

Part F  —  Patient Responsibilities and Obligations

Clause 11.  Duty of Full Disclosure

The Patient agrees to provide Leanova with complete, accurate, and up-to-date information at all times, including:

• Full medical history, including all current and recent diagnoses, previous surgeries, and hospitalisations;

• Complete list of current medications, supplements, herbal preparations, and over-the-counter drugs;

• Known drug allergies and adverse reactions;

• Family history of relevant conditions (thyroid disease, cardiovascular disease, pancreatitis, MEN-2);

• History of eating disorders, substance use, or significant mental health conditions;

• Any change in health status, new diagnosis, or hospitalisation during the Leanova program.

The Patient acknowledges that incomplete or inaccurate disclosure may compromise clinical safety and constitutes a breach of this Agreement.

Clause 12.  Mandatory Notifications

The Patient agrees to notify Leanova promptly — and prior to the next scheduled medication dose or consultation — in the event of any of the following:

• Confirmed or suspected pregnancy, or decision to attempt conception;

• Any new prescription or medication change made by another physician, including antibiotics, hormonal medications, or cardiovascular drugs;

• Hospitalisation or attendance at an emergency department for any reason;

• Development of severe or persistent nausea, vomiting, abdominal pain, or inability to tolerate oral intake;

• Symptoms of pancreatitis: severe persistent upper abdominal pain radiating to the back, with or without vomiting;

• Signs of serious allergic reaction: facial swelling, difficulty breathing, or generalised rash;

• Significant change in mental health, including new suicidal ideation or self-harm;

• Diagnosis of any new significant medical condition.

Clause 13.  Medication Safety and Sourcing

The Patient agrees to obtain all prescribed medications only from verified, licensed pharmacies or dispensaries as directed by Leanova. The Patient acknowledges that medications obtained from unverified sources — including online marketplaces, grey-market suppliers, or compounding pharmacies not approved by Leanova — carry risks of contamination, incorrect dosage, and counterfeiting that may result in serious harm. The Patient accepts full personal responsibility for medications obtained from such sources without Leanova's direction.

The Patient agrees not to share, sell, or transfer prescribed medications to any other person. Medications are prescribed for the patient's specific clinical needs and are not suitable for general use.

Clause 14.  Medication Storage and Administration

The Patient agrees to store and administer all medications strictly in accordance with the instructions provided by the Leanova physician and the manufacturer's guidelines. Injectable medications must be stored at the recommended temperature and administered using the correct technique as demonstrated or instructed. In case of doubt, the Patient will contact Leanova before proceeding.

Clause 15.  Follow-up, Monitoring, and Adherence

The Patient agrees to:

• Attend all scheduled follow-up consultations via the agreed digital channel;

• Complete required laboratory investigations at the intervals recommended by the treating physician;

• Adhere to prescribed medication doses, titration schedules, and dietary guidance;

• Respond to clinical check-in communications from the Leanova team within a reasonable time;

• Report any adverse effects, unusual symptoms, or treatment concerns promptly.

The Patient acknowledges that failure to engage with follow-up and monitoring may compromise treatment safety and clinical outcomes, and may result in the Leanova physician pausing or discontinuing pharmacotherapy until clinical review is completed.

Clause 16.  Concurrent Medical Care

The Patient agrees to inform all other treating physicians, specialists, and pharmacists of their participation in the Leanova program and of all medications prescribed by Leanova, prior to commencing any new medication or treatment. The Patient accepts full responsibility for managing communication between their treating clinicians.

Clause 17.  Emergency Situations

The Patient understands that Leanova is a telemedicine-based elective medical program and is not an emergency medical service. In the event of a medical emergency — including but not limited to suspected anaphylaxis, severe chest pain, stroke symptoms, loss of consciousness, or any life-threatening condition — the Patient must immediately contact emergency services (ambulance/hospital) or present to the nearest emergency department. Leanova should not be contacted as the primary response in an emergency.

Clause 18.  Truthfulness of Declarations

The Patient affirms that all answers provided in the clinical assessment form, all information disclosed during consultations, and all declarations in this Agreement are truthful, complete, and provided to the same standard as if given under oath. The Patient has not omitted or misrepresented any information material to their safety or treatment.

Part G  —  Telehealth Consent

Clause 19.  Consent to Telemedicine

The Patient consents to receive clinical assessments, medical consultations, treatment recommendations, and follow-up care through telemedicine modalities, including audio-video consultation, WhatsApp-based clinical communication, digital form submission, and electronic sharing of medical data.

The Patient acknowledges the following:

• Telemedicine inherently limits the physician's ability to conduct a physical examination, and the treating physician may recommend in-person evaluation by a local physician when clinically necessary;

• Technical failures, including connectivity issues, platform outages, or device malfunctions, may occasionally interrupt care delivery;

• The Patient accepts sole responsibility for ensuring a private, secure environment during consultations and for maintaining the confidentiality of login credentials and shared medical documents;

• Clinical records generated through telemedicine hold the same legal status as those generated during in-person care.

Clause 20.  Communication Records

The Patient consents to Leanova retaining records of clinical communications conducted through its platform, including WhatsApp messages, consultation notes, and written correspondence, for the purposes of care continuity, clinical safety, medico-legal documentation, and compliance with applicable medical record-keeping regulations.

Part H  —  Data Privacy and Confidentiality

Clause 21.  Data Collection and Processing

The Patient acknowledges that Leanova collects and processes personal information and sensitive personal data — including health, metabolic, and clinical records — in accordance with the Leanova Privacy Policy (available at www.leanova.in), the Information Technology Act 2000, the SPDI Rules 2011, and the Digital Personal Data Protection Act 2023. The Patient consents to such collection and processing for the purposes of clinical care, program administration, and compliance with applicable law.

Clause 22.  Sharing with Clinical Partners

The Patient authorises Leanova to share clinical information with affiliated physicians, partner laboratories, dispensing pharmacies, and specialist referral networks as necessary for the delivery of safe, coordinated care. All such disclosures are made only to the extent clinically necessary and are subject to confidentiality obligations.

Clause 23.  No Commercial Data Use

Leanova does not sell, rent, or transfer the Patient's personal or health information to advertisers, data brokers, or commercial third parties. Aggregated and fully anonymised data may be used for research and service improvement purposes only.

Part I  —  Liability Waiver, Release, and Indemnification

Clause 24.  Liability Waiver and Release

In consideration of the medical services provided by Leanova, and with full understanding of the associated risks and limitations as disclosed in this Agreement, the Patient hereby fully and irrevocably releases, waives, and discharges Leanova Health, its directors, officers, supervising physicians, affiliated clinicians, employees, contractors, and partner service providers (collectively, the "Released Parties") from any and all claims, demands, liabilities, causes of action, damages, costs, and expenses — whether in contract, tort, or otherwise — arising from or related to any of the following:

1. The Patient's participation in the Leanova program in any capacity;

2. Any adverse effect, complication, or outcome resulting from prescribed medications, lifestyle recommendations, nutritional guidance, clinical assessments, laboratory referrals, or telemedicine consultations, where such outcomes arose despite clinically reasonable care;

3. The Patient's failure to disclose complete, accurate, and material medical information prior to or during treatment;

4. The Patient's failure to follow medical advice, prescribed dosage protocols, injection instructions, dietary recommendations, or safety guidelines communicated by the Leanova physician;

5. The Patient's procurement of medications from unverified or unapproved sources;

6. Delays, limitations, or interruptions inherent in telemedicine delivery or arising from third-party technology platforms;

7. Actions, omissions, or advice provided by third-party specialists, laboratories, pharmacies, or referral providers to whom the Patient was directed;

8. Any event, circumstance, or outcome arising from factors beyond the reasonable control of the Released Parties.

Clause 25.  Indemnification

The Patient agrees to indemnify, defend, and hold the Released Parties harmless against any claim, demand, loss, liability, judgment, or expense (including reasonable legal fees) arising from the Patient's own actions, omissions, non-adherence to treatment protocols, misrepresentation of information, or breach of any obligation under this Agreement.

Clause 26.  No Guarantee of Outcome

The Patient acknowledges that no employee, physician, or representative of Leanova has made any guarantee, warranty, or promise of a specific weight loss outcome, health improvement, or clinical result. All treatment is provided on the basis of current medical evidence and clinical judgment, with full recognition that individual responses to treatment vary and cannot be predicted with certainty.

Clause 27.  Limitation of Liability

To the extent permitted by applicable Indian law, the aggregate liability of the Released Parties to the Patient for any claim arising under this Agreement shall not exceed the total subscription fees paid by the Patient to Leanova in the three calendar months immediately preceding the event giving rise to the claim.

Part J  —  Financial Obligations and Subscription Terms

Clause 28.  Payment and Subscription

The Patient confirms that they are the authorised account holder or cardholder for the payment method used to purchase the Leanova program subscription. The Patient has not been induced or placed under any duress or undue influence to enrol in the program and does so of their own free will and informed choice.

Clause 29.  Cancellation and Refund

Subscription cancellations and refund requests are governed by Leanova's Cancellation and Refund Policy, which is provided to the Patient at the time of enrolment and is available at www.leanova.in. The Patient acknowledges having reviewed this policy prior to signing this Agreement.

Part K  —  General Provisions

Clause 30.  Governing Law and Jurisdiction

This Agreement shall be governed by and construed in accordance with the laws of India. Any dispute arising out of or in connection with this Agreement shall be subject to the exclusive jurisdiction of the competent courts in India.

Clause 31.  Severability

If any provision of this Agreement is held to be invalid, unlawful, or unenforceable under applicable law, that provision shall be severed from the Agreement, and the remaining provisions shall continue in full force and effect.

Clause 32.  Entire Agreement

This Agreement, read together with Leanova's Privacy Policy and Cancellation Policy, constitutes the entire agreement between the Patient and Leanova with respect to the subject matter herein and supersedes all prior representations, communications, and understandings, whether oral or written.

Clause 33.  Amendments

Leanova reserves the right to update or amend this Agreement. Any material amendments will be communicated to the Patient before their next renewal or clinical interaction, and continued enrolment shall constitute acceptance of the revised terms.